Binding Term Sheet between Austrianova Singapore Pte. Ltd. and SG Austria Pte. Ltd. and PharmaCyte Biotech, Inc.PharmaCyte Biotech, Inc. • September 6th, 2017 • Medicinal chemicals & botanical products
This Binding Term Sheet (“Term Sheet”) summarizes the principal terms of a transaction between Austrianova Singapore Pte. Ltd., a Singapore corporation, with a principal place of business at 3 Biopolis Drive, #05-19 Synapse, Singapore 138623 (“Austrianova Singapore”), SG Austria Pte. Ltd., a Singapore corporation, with a principal place of business at 3 Biopolis Drive, #05-19 Synapse, Singapore 138623 (“SG Austria” and together with Austrianova Singapore, “Austrianova”) and PharmaCyte Biotech, Inc., a Nevada corporation with a principal place of business at 22046 Avenida de la Carlota, Suite 600, Laguna Hills, California 92653, (“PharmaCyte”). The Term Sheet is intended to provide both: (a) guidance in the preparation of more complete written amendments to (i) that certain License Agreement, as amended, dated as of December 1, 2014, by and between PharmaCyte and Austrianova Singapore (“Cannabis License Agreement”), (b) that certain License Agreement, as amended, dated as of June 25, 20
